NYSE: VIE - Viela Bio, Inc.

Yield per half year: 0%
Sector: Healthcare

Share chart Viela Bio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Viela Bio, Inc., биотехнологическая компания, работающая на клинической стадии, занимается исследованиями и разработкой методов лечения тяжелых воспалений и аутоиммунных заболеваний в США. Основным кандидатом на продукцию компании является инебилизумаб, гуманизированное моноклональное антитело для лечения расстройства оптического спектра нейромиелита, десенсибилизации трансплантата почки, миастении и заболеваний, связанных с IgG4. Также разрабатывается VIB4920 для лечения отторжения трансплантации почки и синдрома Шегрена; и VIB7734 для кожной красной волчанки. Viela Bio, Inc.

More details
осуществляет стратегическое сотрудничество с Mitsubishi Tanabe Pharma Corporation по разработке и коммерциализации инебилизумаба для лечения аутоиммунных заболеваний в Японии, Таиланде, Южной Корее, Индонезии, Вьетнаме, Малайзии, Филиппинах, Сингапуре и Тайване. Компания была основана в 2017 году, ее штаб-квартира находится в Гейтерсбурге, штат Мэриленд.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/S 26.03
P/BV 3.67
EV/EBITDA -1.3447
EBITDA 0.0944
Цена ао 53.01
Выручка 0.05
Див.доход ао 0
Валюта usd
ISIN US9266131005
Сайт http://www.vielabio.com
IPO date 2019-10-03
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: 0% (26.55)
Change price per week: 0% (26.55)
Change price per month: 0% (26.55)
Change price per 3 month: 0% (26.55)
Change price per half year: 0% (26.55)
Change price per year: 0% (26.55)
Change price per 3 year: 0% (26.55)
Change price per 5 year: -29.95% (37.9)
Change price per year to date: 0% (26.55)


All parameters ⇨

Underestimation

Title Value Grade
P/S 249.99 1
P/BV 4.87 3
P/E 0 0
EV/EBITDA -16.72 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -23.83 0
ROE, % -41.26 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0151 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -76.6 0
Yield Ebitda, % -260.38 0
Yield EPS, % -29.02 0
Total: 2
More

Institutions Volume Share, %
Fidelity SelectCo, LLC 9007706 16.41
BlackRock Advisors (UK) Limited 7432955 1.1
DWS Investment S.A. 7247749 1.28
Amundi Asset Management 6017220 0.89
Invesco Asset Management Ltd 5503123 0.81
BNP Paribas Asset Management France 5220977 0.77
Moneta Asset Management 4936664 0.87
KBI Global Investors Ltd 4921798 0.73
Fidelity Management & Research Company LLC 4232414 7.71
Temasek Holdings Ltd. 4070330 7.41
La Banque Postale Asset Management 3471253 0.51
Allianz Global Investors GmbH 3265500 0.48
Fidelity Management & Research Company LLC 3051675 5.56
Templeton Investment Counsel LLC 2815282 0.5
Invesco Capital Management LLC 2787289 0.41
HSBC Global Asset Management (France) 2420928 0.36
Hillhouse Capital Advisors, Ltd. 2382414 4.34
Sycomore Asset Management 2358168 0.42
DNCA Finance 2070214 0.31
Covéa Finance 1795800 0.27
HBM Partners Cayman Ltd 1750000 3.19
Cormorant Asset Management, LLC 1585000 2.89
BlackRock Fund Advisors 1409027 2.57
Rothschild & Co Asset Management Europe 1156889 0.17
Eurizon AM SGR S.p.A. 1088005 0.16
Clartan Associés 1078191 0.16
Caixabank Asset Management SGIIC 1025742 0.15
Crédit Mutuel Asset Management 1014781 0.15
Alken Asset Management LLP 853101 0.15
Dorval Asset Management 844607 0.15
SSGA Funds Management Inc 738568 1.35
Federal Finance Gestion 683442 0.1
American Century Investment Management, Inc 558048 1.02
iM Global Partner Asset Management S.A. 549827 0.1
Fidelity Investments 411458 0.75
Northern Trust Investments Inc 381180 0.69
Universal-Investment GmbH 269928 0.04
Meeschaert Asset Management 230639 0.03
State Street Global Advisors 225554 0.41
Palatine Asset Management 222674 0.04
Equitable 162264 0.3
The Variable Annuity Life Insurance Company 73540 0.13
Federated MDTA LLC 58421 0.11
Fidelity Investments Canada ULC 54767 0.1
JPMorgan Chase Bank 47333 0.09
SEI Investments Management Corp 40360 0.07
Pinz Capital Management, LP 31150 0.06
Principal Global Investors, LLC 19368 0.04
SunAmerica Asset Management, LLC 16285 0.03
ETFS Management (AUS) Ltd 2886 0.01
AlphaCentric Advisors LLC 1500 0
Defiance ETFs, LLC 1245 0
PGIM Investments LLC 1099 0
Pharus Asset Management SA 950 0
E Fund Mgmt Co.,Ltd 715 0
Invesco Capital Markets Inc 62 0

ETF Share, % Profitability for 1 year, % Dividends, %
Invesco Global Water ETF 3.95 37.80 0.78
Ecofin Global Water ESG Fund 3.65 44.83 1.37



Head Job title Payment Year of birth
Dr. Zhengbin Yao Chairman, Pres & CEO 1966 (58 years)
Mr. Mitchell Chan Chief Financial Officer 1981 (43 years)
Dr. Jörn Drappa M.D., Ph.D. Chief Medical Officer and Head of R&D 1965 (59 years)
Mr. James Paul Kastenmayer J.D., Ph.D. Gen. Counsel & Company Sec. 1972 (52 years)
Ms. Kate Surdez Sr. VP & Head of HR
Ms. Rachel Ettinger Sr. Director & Head of Research
Mr. Bill Rees Sr. Director & Head of Translational Science
Mr. Ted Phillips VP & Head of Clinical Operations
Mr. Dewei She Sr. Director and Head of Biostatistics, Data Management, & Programming
Mr. Lee Levin Sr. Director & Head of Quality

Address: United States, Gaithersburg, One MedImmune Way - open in Google maps, open in Yandex maps
Website: http://www.vielabio.com